Fresenius Kabi Files Complaint Against Natco Pharma in US, Reports ET HealthWorld

In New Delhi, Natco Pharma is facing a complaint filed by Fresenius Kabi in the US district court over the marketing of Diazepam injection prefilled syringe. The complaint was lodged against Natco Pharma USA LLC by Fresenius Kabi USA, LLC and Fresenius Kabi Deutschland GmbH in the District Court of Delaware. Natco Pharma had acquired Dash Pharmaceuticals LLC, which had renamed itself Natco Pharma USA LLC.

The complaint has not been served officially by Fresenius to commence the lawsuit against Natco Pharma. However, Natco Pharma has stated its intention to defend the matter accordingly. Diazepam injection is commonly used in the treatment of anxiety, muscle spasms, and alcohol withdrawal.

Fresenius Kabi’s complaint against Natco Pharma in the United States revolves around the marketing of Dash Pharmaceuticals’ Diazepam Injection prefilled syringe. The regulatory filing by Natco Pharma indicates that the company is prepared to address and counter the legal action taken by Fresenius Kabi. Natco Pharma continues to assert its position in the case and vows to defend its marketing practices of the Diazepam injection prefilled syringe in the US market.